JP2016513722A - 腎臓病及び他の疾患の治療方法 - Google Patents

腎臓病及び他の疾患の治療方法 Download PDF

Info

Publication number
JP2016513722A
JP2016513722A JP2016502687A JP2016502687A JP2016513722A JP 2016513722 A JP2016513722 A JP 2016513722A JP 2016502687 A JP2016502687 A JP 2016502687A JP 2016502687 A JP2016502687 A JP 2016502687A JP 2016513722 A JP2016513722 A JP 2016513722A
Authority
JP
Japan
Prior art keywords
patient
metap2 inhibitor
administering
effective amount
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513722A5 (cg-RX-API-DMAC7.html
Inventor
ヒューズ，トーマス，イー．
ヴァス，ジェームズ，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Larimar Therapeutics Inc
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of JP2016513722A publication Critical patent/JP2016513722A/ja
Publication of JP2016513722A5 publication Critical patent/JP2016513722A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016502687A 2013-03-14 2014-03-14 腎臓病及び他の疾患の治療方法 Pending JP2016513722A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781926P 2013-03-14 2013-03-14
US61/781,926 2013-03-14
US201361787769P 2013-03-15 2013-03-15
US61/787,769 2013-03-15
PCT/US2014/028022 WO2014152861A2 (en) 2013-03-14 2014-03-14 Methods of treating renal disease and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018211890A Division JP2019019146A (ja) 2013-03-14 2018-11-12 腎臓病及び他の疾患の治療方法

Publications (2)

Publication Number Publication Date
JP2016513722A true JP2016513722A (ja) 2016-05-16
JP2016513722A5 JP2016513722A5 (cg-RX-API-DMAC7.html) 2017-04-06

Family

ID=50736155

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502687A Pending JP2016513722A (ja) 2013-03-14 2014-03-14 腎臓病及び他の疾患の治療方法
JP2018211890A Pending JP2019019146A (ja) 2013-03-14 2018-11-12 腎臓病及び他の疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018211890A Pending JP2019019146A (ja) 2013-03-14 2018-11-12 腎臓病及び他の疾患の治療方法

Country Status (10)

Country Link
US (3) US9597309B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968250B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016513722A (cg-RX-API-DMAC7.html)
KR (1) KR20150126924A (cg-RX-API-DMAC7.html)
CN (1) CN105228610A (cg-RX-API-DMAC7.html)
AU (2) AU2014236528A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023390A2 (cg-RX-API-DMAC7.html)
CA (1) CA2904353A1 (cg-RX-API-DMAC7.html)
MX (1) MX362391B (cg-RX-API-DMAC7.html)
WO (1) WO2014152861A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2968250B1 (en) 2013-03-14 2019-06-19 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075020A1 (en) * 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
EP0359036B1 (en) 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
EP0387650B1 (en) 1989-03-06 1993-03-31 Takeda Chemical Industries, Ltd. 6-epifumagillols, production and use thereof
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (cg-RX-API-DMAC7.html) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP0555693B1 (en) 1992-01-30 2001-09-05 Takeda Chemical Industries, Ltd. Method of producing highly watersoluble cyclodextrin complex
ATE153854T1 (de) 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
US5900431A (en) 1995-03-27 1999-05-04 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
CA2234401A1 (en) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
ES2224465T3 (es) 1997-10-31 2005-03-01 Children's Medical Center Corporation Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado.
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100293504B1 (ko) 1998-06-05 2001-07-12 김윤 서방형전립선염치료제조성물
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CN1183113C (zh) 1999-04-28 2005-01-05 阿文蒂斯药物德国有限公司 作为ppar受体配体的三芳基酸衍生物
WO2001024796A1 (en) 1999-10-01 2001-04-12 Smithkline Beecham Corporation 1,2,4-triazole derivatives, composition, process of making and methods of use
JP2003530438A (ja) 2000-04-12 2003-10-14 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AR030631A1 (es) 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
AU2002239479B2 (en) 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
EP1379241A1 (en) 2001-03-29 2004-01-14 SmithKline Beecham Corporation Compounds and methods
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US7087768B2 (en) 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
JP2005508951A (ja) 2001-10-12 2005-04-07 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
EP1512047A4 (en) 2002-06-12 2008-03-05 Silicon Optix Inc AUTOMATIC KEYSTONE CORRECTION SYSTEM AND METHOD
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US20050239878A1 (en) 2003-12-29 2005-10-27 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
WO2006004803A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
WO2006010498A2 (en) 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1841761A4 (en) 2005-01-26 2008-10-29 Chong Kun Dang Pharm Corp Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2006138475A2 (en) 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
AU2008331516B2 (en) 2007-11-28 2014-01-09 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CN102123586A (zh) * 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
WO2010042163A2 (en) 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
CA2741683C (en) 2008-10-24 2016-03-22 Wake Forest University Platinum acridine anti-cancer compounds and methods thereof
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065879A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
CN102791699B (zh) 2010-01-08 2016-04-06 扎夫根公司 烟曲霉醇型化合物和其制造和使用方法
US8815309B2 (en) * 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US20130023513A1 (en) * 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
WO2011150338A1 (en) 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
BR112013008856A2 (pt) 2010-10-12 2016-06-21 Zafgen Inc compostos de sulfonamida e métodos pra fazer e usar os mesmos
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012075026A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of treating obesity using an effective dose of a metap-2 inhibitor
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
CA2861390A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
EP2850079B1 (en) 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
EP2968250B1 (en) 2013-03-14 2019-06-19 Zafgen, Inc. Methods of treating renal disease and other disorders
KR20150074414A (ko) 2013-12-24 2015-07-02 현대자동차주식회사 펌웨어 업그레이드 방법 및 그 시스템

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075020A1 (en) * 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CELLULAR PHYSIOLOGY, vol. 227, JPN6017040720, 2011, pages 239 - 249, ISSN: 0003832171 *
JOURNAL OF EXPERIMENTAL AND CLINICAL MEDICINE, vol. 4, no. 3, JPN6017040721, 2012, pages 145 - 148, ISSN: 0003832172 *

Also Published As

Publication number Publication date
MX2015012164A (es) 2016-05-16
JP2019019146A (ja) 2019-02-07
US10231946B2 (en) 2019-03-19
CN105228610A (zh) 2016-01-06
US9597309B2 (en) 2017-03-21
KR20150126924A (ko) 2015-11-13
WO2014152861A3 (en) 2014-11-20
US20180085338A1 (en) 2018-03-29
BR112015023390A2 (pt) 2017-07-18
AU2014236528A1 (en) 2015-09-24
US9849106B2 (en) 2017-12-26
EP2968250A2 (en) 2016-01-20
WO2014152861A2 (en) 2014-09-25
US20170333383A1 (en) 2017-11-23
EP2968250B1 (en) 2019-06-19
MX362391B (es) 2019-01-15
US20160038453A1 (en) 2016-02-11
AU2018282489A1 (en) 2019-01-24
CA2904353A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
Li et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy
TWI835179B (zh) 胰腺炎治療
Clement et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome
US9421208B2 (en) Methods for the treatment of solid tumors
ES3015717T3 (en) A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis
Pelletier et al. White adipose tissue overproduces the lipid-mobilizing factor zinc α2-glycoprotein in chronic kidney disease
US20130316994A1 (en) Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
Byun et al. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway
JP2010539078A (ja) ジメチルフマレートの新規な用途
Khan et al. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat
JP2019019146A (ja) 腎臓病及び他の疾患の治療方法
Bonnard et al. Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
Wang et al. Ethyl caffeate inhibits macrophage polarization via SIRT1/NF-κB to attenuate traumatic heterotopic ossification in mice
Yang et al. Hyperoside attenuates osteoarthritis progression by targeting PI3K/Akt/NF-κB signaling pathway: in vitro and in vivo studies
Kong et al. Akt2 deficiency alleviates oxidative stress in the heart and liver via up-regulating SIRT6 during high-fat diet-induced obesity
CN113181160A (zh) 异硫氰酸酯类化合物的用途
Doedens et al. Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1, 2, 3, 5, 6, 7-Hexahydro-s-indacen-4-yl) carbamoyl][(1-methyl-1 H-pyrazol-4-yl)({[(2 S)-oxolan-2-yl] methyl}) sulfamoyl] azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework
US20180133169A1 (en) Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient
JP2010539079A (ja) スコパロンの新規な用途
Sharma et al. Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia–A Review
CA3212016A1 (en) Treatment of copper disorders
Kojovic et al. Regulation of drug transporters by inflammation
Zhang et al. Pegylation enhances the anti-osteoporosis activity of acacetin in both ovariectomized and LPS-stimulated mice
Liu et al. Cyy-272, an indazole derivative, effectively mitigates obese cardiomyopathy as a JNK inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180710